The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-20 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
=== Use === Voluntary use by the public was ineffective. A lack of features and bugs further reduced usefulness. Some apps include "check-ins" that enable exposure notifications when entering public venues such as fitness centres. One such example is the We-Care project that used anonymity and crowdsourced information about which check-ins are essential, to alert exposed users.
=== Psychosis model === Early studies of DET as well as other psychedelics were focused on their presumed psychotomimetic properties. Researchers theorized that abnormal metabolites of endogenous chemicals such as tryptamine, serotonin, and tryptophan could be the explanation for mental disorders such as schizophrenia, or psychosis. DET, along with other synthetic psychedelics, was administered to both patients and healthy volunteers to understand its effects and as a possible biological model for psychosis. With the progression of science and pharmacological understanding, this belief has been dismissed by most researchers.
=== Basic research and translational preclinical animal model research === Jennette, in collaboration with Falk, and UNC faculty associates Hong Xiao and Peiqi Hu, and other faculty and trainees, made multiple discoveries about the cellular and molecular mechanisms that cause ANCA disease. He, Falk, and their research associates published the first demonstration that ANCA can activate neutrophils in vitro, and the first in vivo animal model confirming that ANCA antibodies cause glomerulonephritis by inducing glomerulonephritis and vasculitis in mice by intravenous injection of anti-MPO antibodies. This model has been used to make discoveries about the pathogenesis of ANCA disease, including the discovery of a key role for alternative complement pathway activation and C5a receptor engagement, which can be targeted by a novel small molecular inhibitor of C5a receptor (Avacopan). This approach to therapy was FDA-approved for patient care in 2021.
=== Design of globular proteins === Globular proteins are proteins that contain a hydrophobic core and a hydrophilic surface. Globular proteins often assume a stable structure, unlike fibrous proteins, which have multiple conformations. The three-dimensional structure of globular proteins is typically easier to determine through X-ray crystallography and nuclear magnetic resonance than both fibrous proteins and membrane proteins, which makes globular proteins more attractive for protein design than the other types of proteins. Most successful protein designs have involved globular proteins. Both RSD-1, and Top7 were de novo designs of globular proteins. Five more protein structures were designed, synthesized, and verified in 2012 by the Baker group. These new proteins serve no biotic function, but the structures are intended to act as building-blocks that can be expanded to incorporate functional active sites. The structures were found computationally by using new heuristics based on analyzing the connecting loops between parts of the sequence that specify secondary structures.
Sources: en.wikipedia.org
In recent years, the clinical understanding of the FDA's "black box" warning has evolved to focus on the balance between medication risks and the risks of untreated depression. While the 2004 and 2006 warnings regarding increased suicidal ideation in children and young adults (under 25) remain, long-term data published through 2024 suggests that these warnings may have led to an unintended decline in depression treatment, which some studies correlate with an increase in suicide deaths among adolescents. Statistical meta-analyses updated in 2022 confirm that while the risk of suicidal thoughts in youth on antidepressants like fluoxetine is approximately twice that of a placebo (4% vs 2%), there remains no statistically significant increase in completed suicides across dozens of pediatric trials. Furthermore, recent data continues to show a protective effect in older populations; for adults aged 65 and older, antidepressant use is associated with a statistically significant decrease in suicidality. Regarding specific treatments, research published between 2021 and 2023 reinforces that fluoxetine is most effective and carries the lowest risk of adverse behavioral events when paired with psychotherapy. A 2022 meta-analysis found that combination therapy (medication plus CBT) resulted in a lower incidence of suicidal events compared to fluoxetine alone.
Requires Supplemental Nutrition Assistance Program (federal food assistance) beneficiaries ages 18 to 64 to work at least 80 hours per month, compared to ages 18 to 54 under current law; Requires states with an error rate above 6% to contribute to up to 15% of SNAP benefit costs. Alaska and Hawaii received special exemptions for these effective cuts after lobbying from senators Lisa Murkowski and Dan Sullivan; Repeals the National Education and Obesity Prevention Grant Program; Reduces federal nutrition funding by $186 billion between 2025 and 2034. Increases the share of state costs to administer the SNAP program from 50% to 75%; and Restricts future updates to the Thrifty Food Plan used to calculate SNAP benefit levels.
== Contributions to Science == Alexander von Humboldt’s scientific achievements are notable for their scope, empirical rigor, and transformative impact across the natural sciences. His American expedition (1799–1804) produced a vast array of new data and observations, which he synthesized in a remarkable body of published work. Humboldt’s enduring reputation is grounded in his relentless fieldwork, his innovative methods of data visualization, and above all in his vision of nature as a unified and dynamic system. His contributions to plant geography are evident in his Essai sur la géographie des plantes (1805), which introduced the idea that plant distributions are determined by environmental factors such as climate, elevation, and soil. This groundbreaking work was based on his ascent of equatorial mountains like Chimborazo and Pichincha, where he meticulously recorded changes in vegetation corresponding to altitude and temperature. Humboldt’s iconic “Chimborazo profile” visually mapped plant zones along the mountain’s slopes, integrating botanical, meteorological, and physical data. By demonstrating that the same climatic zones could produce similar vegetation types on different continents, Humboldt laid the foundations for modern biogeography and ecology, moving beyond Linnaean taxonomy to a dynamic understanding of the relationship between organisms and their environment.
Sources: en.wikipedia.org
== Medical uses == Lurasidone is used to treat schizophrenia and bipolar disorder. In bipolar disorder, it has been studied both as a monotherapy and adjunctive treatment to lithium or valproate. The European Medicines Agency approved lurasidone for the treatment of schizophrenia for people aged 13 years and older. Its use in Europe for bipolar disorder is considered off-label. In the United States, it is used to treat schizophrenia for people aged 13 years and older. In July 2013, lurasidone received approval for bipolar I depression. This includes depressive episodes of bipolar disorder age 10 and over as a monotherapy, and in conjunction with lithium or valproate in adults. In June 2020, lurasidone was approved in Japan, eight years after its first approval in the United States. In Japan it is approved for bipolar depression and schizophrenia. Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being cariprazine, quetiapine, olanzapine and possibly asenapine) as a monotherapy. The majority of atypical antipsychotics are known to possess significant antimanic activity, however lurasidone is unusual as it was never studied for acute mania.
== General consequences == Point mutations that occur in non-coding sequences are most often without consequences, although there are exceptions. If the mutated base pair is in the promoter sequence of a gene, then the expression of the gene may change. Also, if the mutation occurs in the splicing site of an intron, then this may interfere with correct splicing of the transcribed pre-mRNA. By altering just one amino acid, the entire peptide may change, thereby changing the entire protein. The new protein is called a protein variant. If the original protein functions in cellular reproduction then this single point mutation can change the entire process of cellular reproduction for this organism. Point germline mutations can lead to beneficial as well as harmful traits or diseases. This leads to adaptations based on the environment where the organism lives. An advantageous mutation can create an advantage for that organism and lead to the trait's being passed down from generation to generation, improving and benefiting the entire population. The scientific theory of evolution is greatly dependent on point mutations in cells. The theory explains the diversity and history of living organisms on Earth. In relation to point mutations, it states that beneficial mutations allow the organism to thrive and reproduce, thereby passing its positively affected mutated genes on to the next generation. On the other hand, harmful mutations cause the organism to die or be less likely to reproduce in a phenomenon known as natural selection.
The Gaddafi–Abdullah feud came into public view again in the 2009 Arab League summit when Gaddafi accused Abdullah, who had become King of Saudi Arabia in 2005, of being created by Britain and protected by the US. Alluding to their 2003 altercation, Gaddafi taunted Abdullah for ostensibly avoiding a confrontation with him for six years and quoted Abdullah's 2003 "grave awaits you" threat back at him before storming out of the meeting to visit a museum. Abdullah also left the meeting hall in anger. A Saudi official later claimed that Gaddafi and Abdullah had held a 30 minutes meeting at the sideline of the summit and that the "personal problem" between them was "over". However, Gaddafi had given weapons and money to the Houthis to attack Saudi Arabia.
=== In vivo approaches === The first direct evidence for in vivo persistence of intrinsic disorder has been achieved by in-cell NMR upon electroporation of a purified IDP and recovery of cells to an intact state. This was achieved in 2016. In vivo biotinylation was originally used to study which proteins come in the proximity of each other (proximity tagging). It was hypothesized and proven in 2018 that biotinylation favors intrinsically disordered regions as they are more accessible. Although the association between biotinylation and disorder is not absolute, the preference is strongly suggestive of a disordered state in vivo. Because biotinylation status can be checked for a large number of residues at the same time, large-scale biotin "painting" can identify many likely disordered regions at the same time.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.